2026-09-28 日報 ⌂

🩺 醫藥健康每日摘要 - 第 248 期 (2026-09-28)

重點導讀

1. 一種 CRISPR 療法能將「壞」膽固醇減半,效果持續一年(One CRISPR treatment cut “bad” cholesterol in half for a full year)

分析段落:這是一項潛在的重大突破,利用 CRISPR 技術單次給藥就能大幅且長期地降低 LDL 膽固醇和三酸甘油酯,對於難治性血脂異常患者而言,這可能意味著一種革命性的治療新選擇,大幅降低心血管疾病的風險。
- 原文連結:https://www.sciencedaily.com/releases/2026/09/260925005434.htm

2. GLP-1 藥物有望擴大適用範圍,數百萬超重者可能受益於心臟保護(Millions more people with overweight could benefit from GLP-1 drugs to protect heart health, study suggests)

分析段落:這項研究提議將 GLP-1 受體激動劑的適應症擴展至更多體重過重者,以保護心臟健康,顯示這類藥物在心血管預防方面的潛力巨大,可能影響數百萬人的治療方針。
- 原文連結:https://medicalxpress.com/news/2026-09-millions-people-overweight-benefit-glp.html

3. 類器官中的腸道微生物組可揭示第二型糖尿病風險(Gut microbiome can reveal risk of type 2 diabetes)

分析段落:新研究表明,腸道菌群組成的變化或許能預警第二型糖尿病的發生,為早期診斷和預防策略提供新方向,這對於因應全球日益嚴峻的糖尿病流行病具有重要意義。
- 原文連結:https://medicalxpress.com/news/2026-09-gut-microbiome-reveal-diabetes.html

4. 類風濕性關節炎的疼痛即使在發炎受控後仍可能持續,部分原因與心理和生活型態有關(Why rheumatoid arthritis pain may persist even when inflammation is under control)

分析段落:研究發現,類風濕性關節炎的疼痛與疲勞可能持續存在,即使發炎獲得控制,而憂鬱、睡眠品質、肥胖、抽菸等因素扮演關鍵角色。這將有助於制定更個人化、多面向的治療計畫。
- 原文連結:https://www.sciencedaily.com/releases/2026/09/260925093208.htm

5. 葡萄糖胺與阿茲海默症的快速進展有關聯(Glucosamine, a popular joint supplement, linked to faster Alzheimer’s progression)

分析段落:一項針對龐大健康紀錄的分析指出,服用葡萄糖胺與輕度認知障礙惡化為失智症的機率增加有關。儘管需要更多臨床試驗證實,但此發現對廣泛使用的關節保健品敲響了警鐘。
- 原文連結:https://www.sciencedaily.com/releases/2026/09/260927033754.htm

6. 美國官員明知輝瑞疫苗安全監測系統有缺陷,卻將提出警示的 FDA 醫師排除在外(US officials knew covid vaccine safety system was flawed—but turned aside the FDA doctor who alerted them)

分析段落:此報導揭露了 COVID-19 疫苗安全監測系統的潛在問題,以及相關部門在面對警訊時的處理方式,這對於疫苗監管的透明度和公眾信任度提出了嚴峻挑戰。
- 原文連結:https://www.bmj.com/content/394/bmj-2026-100806/rr-9

7. 加州學校菜單淘汰超加工食品將面臨挑戰(Cutting ultra-processed food from school menus will be tricky, study suggests)

分析段落:根據一項史丹佛醫學研究,加州新法要求公立學校在 2029 年起逐步淘汰高糖、高脂、高鹽及部分人工添加物的超加工食品,此舉雖有利兒童健康,但執行上可能充滿挑戰。
- 原文連結:https://medicalxpress.com/news/2026-09-ultra-food-school-menus-tricky.html

精細分類

Evidence (實證醫學)

  • 評論:實證醫學的新鮮度。(Re: The newness of "evidence-based medicine.")
    本文是對「實證醫學」概念新穎性的批評進行的回應,討論了實證醫學的演變與實踐中的挑戰。

  • 評論:對美國官員明知 COVID-19 疫苗安全監測系統缺陷,卻將提出警示的 FDA 醫師排除在外的報導的回應。(Re: US officials knew covid vaccine safety system was flawed—but turned aside the FDA doctor who alerted them)
    這是一篇對 BMJ 報導的回應,詳細討論了美國官方在 COVID-19 疫苗安全監測系統問題上,以及對提出警示的 FDA 醫師的處理方式。

  • 評論:來自印度的精神科診所的財務困境觀點。(Financial hardship in the psychiatry clinic: a view from India)
    此文透過印度精神科診所的視角,探討了患者面臨的財務困境,並對相關的醫療體系提出反思。

  • 評論:健康的懷疑論應雙向進行:屍檢的角色。(Healthy scepticism should work both ways: the role of the autopsy)
    作者藉由自身診斷經驗,探討了對檢驗結果的懷疑論態度,並強調了屍檢在醫學診斷與研究中的重要性。

  • 評論:轉診路徑在兩端都需要有足夠的承載能力。(Referral pathways need capacity at both ends)
    此評論針對現有的轉診路徑提出建議,認為不僅需要順暢的轉介機制,前端的醫療服務和後端的承接能力都必須充足,才能有效運作。

Clinical (臨床研究與應用)

Guideline (醫療指引與政策)

Pharma (藥物研發與產業)

AI Medicine (AI 醫療應用)

Public Health (公共衛生)

Nutrition & Lifestyle (營養與生活型態)

  • 紅肉中的糖分子與第二型糖尿病風險增加有關。(Sugar molecule in red meat linked to higher risk of developing type 2 diabetes)
    初步研究顯示,攝取大量存在於紅肉中的糖分子 Neu5Gc,與第二型糖尿病風險增加 63% 有關,即使考慮其他風險因素後,此關聯性仍然存在。

  • 葡萄糖胺,一種流行的關節補充劑,與阿茲海默症的快速進展有關。(Glucosamine, a popular joint supplement, linked to faster Alzheimer’s progression)
    一項對龐大健康紀錄的分析發現,服用葡萄糖胺與輕度認知障礙發展為失智症的機率增加 25% 有關,實驗室研究顯示它可能加劇阿茲海默症大腦的異常糖化過程。

Other (其他未分類)

  • 萊索托最鼓舞人心的夜校可能景象。(Photos: This may be the most inspirational night school on Earth)
    在萊索托,許多牧童因學業中斷,一個小型、資源有限的夜校網絡正努力為他們提供基礎教育。

  • 從教授到病患:一位男性在肺癌治療前沿的旅程。(From professor to patient: One man's journey on the frontier of lung cancer treatment)
    報導講述了一位從教授轉變為肺癌病患的個人經歷,並探討了肺癌治療領域的新進展,特別是 mRNA 技術的應用前景。

  • 謝璿/橋頭,誰的更好生活?(謝璿/橋頭,誰的更好生活?)
    這篇文章探討了橋頭新市鎮開發與保存之間的爭議,以及土地利用規劃對在地居民生活與記憶的影響。

  • 健康日曆:所有的大人都曾經是孩子,但很少人記得這點。(健康日曆|所有的大人都曾經是孩子,但很少人記得這點(《小王子》))
    這篇「健康日曆」引用《小王子》名言,探討了「內在小孩」的概念,強調童年經驗與情緒對成人生活的影響。


English Daily Highlights

This report summarizes the latest developments in medicine and health as of September 28, 2026. Key highlights include a significant breakthrough in cholesterol management, potential expansion of GLP-1 drug applications for cardiovascular health, and new insights into diabetes risk prediction through the gut microbiome.

A notable advancement comes from Science Daily Health with the announcement that a single dose of an experimental CRISPR therapy has successfully halved "bad" cholesterol (LDL) and triglycerides in patients with difficult-to-treat lipid disorders, with effects lasting for a full year. This groundbreaking development offers a potential paradigm shift in managing hyperlipidemia and reducing cardiovascular disease risk.

In the realm of metabolic and cardiovascular health, Medicalxpress reports that millions more individuals with overweight conditions could benefit from GLP-1 receptor agonists for heart protection. The study suggests expanding the indication for these widely used drugs, highlighting their broader cardiovascular benefits beyond diabetes management. Complementing this, Medicalxpress also notes that changes in the gut microbiome composition may serve as an early warning sign for type 2 diabetes, opening new avenues for preventative strategies and early diagnosis.

Clinical research also sheds light on rheumatoid arthritis, where Science Daily Health reveals that pain and fatigue can persist even when inflammation is controlled. The study identifies contributing factors such as depression, poor sleep, obesity, and smoking, underscoring the need for personalized and multifaceted treatment approaches.

In public health and policy, Medicalxpress discusses the challenges schools in California may face in phasing out ultra-processed foods from their menus starting in 2029, despite the anticipated health benefits for students. Meanwhile, BMJ features critical responses regarding the U.S. officials' handling of flaws in the COVID-19 vaccine safety monitoring system and the sidelining of an alerting FDA doctor, raising questions about transparency and regulatory oversight.

Finally, Science Daily Health explores a novel approach to cancer treatment research, suggesting that studying cat cancer genetics could unlock better treatments for humans due to surprising genetic similarities found between feline and human tumors. This cross-species research could accelerate precision oncology for both pets and people.